Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis

Alimohamadi, Yousef; Sepandi, Mojtaba; Taghdir, Maryam; Hosamirudsari, Hadiseh

doi:10.15167/2421-4248/jpmh2020.61.3.1530

Cited by 179 publications

(138 citation statements)

References 50 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Headache, fever, vomiting, coughing, and visual disturbances were commonly reported, before progressing to more severe/intense neurological symptoms. 36 This might have an implication on CSF testing for diagnostic purposes. Further studies are required to define whether CSF SARS-CoV-2 testing is warranted in certain clinical contexts.…”

Section: Discussionmentioning

confidence: 99%

Characteristics of Patients with SARS-CoV-2 Positive Cerebrospinal Fluid: A Systematic Review

Salman¹,

Mallah²,

Khalid³

et al. 2021

IJGM

View full text Add to dashboard Cite

Background The coronavirus disease 2019 (COVID-19) has been shown to affect several systems, notably the respiratory system. However, there has been considerable evidence implicating the nervous system in COVID-19 infection. This study aims to investigate the clinical characteristics of patients whose cerebrospinal fluid (CSF) tested positive for SARS-CoV-2. Methods A comprehensive search of PubMed, EMBASE, Scopus, WHO Coronavirus database, bioRxiv, medRxiv, and Web of Science databases was carried out in August 2020. Original studies involving patients who tested positive for SARS-COV-2 in their CSF were included. Key search terms encompassed all variations of “COVID-19” AND “Cerebrospinal Fluid”. Results A total of 525 studies were identified. Fifty-six full-text articles were assessed, of which 14 were included. In total, 14 patients tested positive for SARS-CoV-2 in their CSF. 21.4% (3/14) of patients had negative nasopharyngeal (NP) swabs despite a positive CSF sample. About 14.2% (2/14) of patients who initially had positive NP swabs developed neurological deterioration after a supposed recovery as indicated by their negative NP swabs, but their CSF still tested positive for SARS-CoV-2. Common symptoms were headache (42.8%; 6/14), fever (35.6%; 5/14), vomiting (28.6%; 4/14), cough (28.6; 4/14), visual disturbances (28.6%; 4/14), diarrhea (21.4%; 3/14), and seizures (21.4%; 3/14). Four patients (28.6%) were admitted to ICU, one (7.14%) was admitted to a rehabilitation facility, and two (14.3%) died. Conclusion Physicians should be familiar with the presenting neurological features of COVID-19, and be aware that they can occur despite a negative NP swab. The results of this study are intended to aid in the development of informed guidelines to diagnose and treat COVID-19 patients with neurological manifestations.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics of Patients with SARS-CoV-2 Positive Cerebrospinal Fluid: A Systematic Review

Salman¹,

Mallah²,

Khalid³

et al. 2021

IJGM

View full text Add to dashboard Cite

show abstract

“…However, symptoms like fever, cough, and shortness of breath are considered typical of COVID-19. 32 These symptoms may progress to acute respiratory distress syndrome (ARDS) that requires intensive care. 33 …”

Section: Clinical Signsmentioning

confidence: 99%

Recent Advancements on COVID-19: A Comprehensive Review

Rahman¹,

Abdulateef²,

Hussen³

et al. 2021

IJGM

View full text Add to dashboard Cite

Over the last few decades, there have been several global outbreaks of severe respiratory infections. The causes of these outbreaks were coronaviruses that had infected birds, mammals and humans. The outbreaks predominantly caused respiratory tract and gastrointestinal tract symptoms and other mild to very severe clinical signs. The current coronavirus disease-2019 (COVID-19) outbreak, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a rapidly spreading illness affecting millions of people worldwide. Among the countries most affected by the disease are the United States of America (USA), India, Brazil, and Russia, with France recording the highest infection, morbidity, and mortality rates. Since early January 2021, thousands of articles have been published on COVID-19. Most of these articles were consistent with the reports on the mode of transmission, spread, duration, and severity of the sickness. Thus, this review comprehensively discusses the most critical aspects of COVID-19, including etiology, epidemiology, pathogenesis, clinical signs, transmission, pathological changes, diagnosis, treatment, prevention and control, and vaccination.

show abstract

“…Clinical symptoms of this severe acute respiratory syndrome (SARS) manifest primarily in the upper and lower respiratory tracts. They include dry cough, fever, shortness of breath, sore throat, fatigue, nasal congestion, myalgia, chills, dizziness, and in some, loss of smell and taste [ 3 ]. The severity of these manifestations varies between individuals – in particular, the worsening prognosis was associated with an increase in age and/or the presence of underlying chronic or immunodeficiency disorders [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle

Kumar

Paul

Yadav

et al. 2022

Computers in Biology and Medicine

View full text Add to dashboard Cite

The advent and persistence of the Severe Acute Respiratory Syndrome Coronavirus – 2 (SARS-CoV-2)-induced Coronavirus Disease (COVID-19) pandemic since December 2019 has created the largest public health emergency in over a century. Despite the administration of multiple vaccines across the globe, there continues to be a lack of approved efficacious non-prophylactic interventions for the disease. Flavonoids are a class of phytochemicals with historically established antiviral, anti-inflammatory and antioxidative properties that are effective against cancers, type 2 diabetes mellitus, and even other human coronaviruses. To identify the most promising bioactive flavonoids against the SARS-CoV-2, this article screened a virtual library of 46 bioactive flavonoids against three promising targets in the SARS-CoV-2 life cycle: human TMPRSS2 protein, 3CLpro, and PLpro. By examining the effects of glycosylation and other structural-activity relationships, the presence of sugar moiety in flavonoids significantly reduces its binding energy. It increases the solubility of flavonoids leading to reduced toxicity and higher bioavailability. Through protein-ligand contact profiling, it was concluded that naringin formed more hydrogen bonds with TMPRSS2 and 3CLpro. In contrast, hesperidin formed a more significant number of hydrogen bonds with PLpro. These observations were complimented by the 100 ns molecular dynamics simulation and binding free energy analysis, which showed a considerable stability of docked bioflavonoids in the active site of SARS-CoV-2 target proteins. Finally, the binding affinity and stability of the selected docked complexes were compared with the reference ligands (camostat for TMPRSS2, GC376 for 3CLpro, and GRL0617 for PLpro) that strongly inhibit their respective SARS-COV-2 targets. Overall analysis revealed that the selected flavonoids could be potential therapeutic agents against SARS-CoV-2. Naringin showed better affinity and stability for TMPRSS2 and 3CLpro, whereas hesperidin showed a better binding relationship and stability for PLpro.

show abstract

Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis

Cited by 179 publications

References 50 publications

Characteristics of Patients with SARS-CoV-2 Positive Cerebrospinal Fluid: A Systematic Review

Characteristics of Patients with SARS-CoV-2 Positive Cerebrospinal Fluid: A Systematic Review

Recent Advancements on COVID-19: A Comprehensive Review

A multi-targeted approach to identify potential flavonoids against three targets in the SARS-CoV-2 life cycle

Contact Info

Product

Resources

About